Carolyn Bertozzi, a Stanford professor and serial biotech founder, has been awarded this year’s Nobel Prize in chemistry along with two other scientists, the Royal Swedish Academy of Sciences announced Wednesday.
She shares her prize with Morten Meldal, of the University of Copenhagen in Denmark, and K. Barry Sharpless, a former Nobel prize winner from the Scripps Research Institute in California. Meldal and Sharpless pioneered the concept of “click chemistry,” an idea describing how molecular building blocks snap together in chemical reactions.
Bertozzi took their work one step further, developing “bioorthogonal” click reactions that work inside living cells and don’t disrupt the cell’s normal chemistry. Her approach is used globally to map out cells and track biological processes, the academy said, and is behind targeted cancer treatments now being developed.
Bertozzi has also made a name for herself within the biotech industry, co-founding at least seven companies within the past 12 years. According to an interview with C&EN, her entrepreneurial push came when one of her graduate students asked for guidance in launching a company. Since then, she has continued to help launch startups based on technologies coming out of her laboratory at Stanford. The biotechs share a common foundation built on her work mapping sugar molecules called glycans that are found on cell surfaces, C&EN wrote. READ MORE
By Delilah Alvarado
Source: biopharmadive.com
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.